The first patient with small cell lung cancer has been dosed in a phase 1/2 trial investigating first-line iadademstat plus ...

Q1 2025 Management View Executive Chairman Bill Doyle highlighted the company’s transition to a multi-indication oncology ...

Robotic-assisted thoracic surgery for lung cancer showed a short learning curve and strong outcomes, with 5-year survival rates comparable to open surgery.

Purdue University scientists have identified the Supinoxin molecule as a possible new therapy for small cell lung cancer.

Cindy was a healthy, 35-year-old woman with no symptoms of cancer when she joined the American Lung Association’s Lung Health ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

Patients in Medicaid expansion states had more timely treatment, a study from the Houston-based University of Texas MD Anderson Cancer Center found. The study, published April 11 in The Annals of ...

“The CE Mark approval for Optune Lua for metastatic non-small cell lung cancer is a significant milestone ... ii Physicians use different combinations of surgery, radiation and pharmacological ...

The first-line combination of amivantamab-vmjw plus lazertinib extended OS compared with osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer, according to data from the ...

A new study published in The Annals of Thoracic Surgery, the flagship journal from The Society of Thoracic Surgeons, suggests that Medicaid expansion under the Affordable Care Act has significantly ...

Novocure (NASDAQ: NVCR) announced today that Optune Lua® has received a CE (Conformité Européenne) Mark for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) ...